At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 436 enrolled
Drug / intervention
Netarsudil/Latanoprost 0.02%/0.005% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Double-masked, Randomized, Multicenter, Active-controlled, Parallel-group, 6-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to GANFORT® (Bimatoprost 0.03% / Timolol 0.5%) Ophthalmic Solution in Subjects With Elevated Intraocular Pressure (MERCURY 3)
In Brief
A Phase 3 clinical trial evaluating Netarsudil/Latanoprost 0.02%/0.005% and GANFORT® for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 436 participants across 68 sites in 11 countries.
Detailed Summary
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
CountriesAustria, Belgium, Czechia, France, Germany, Hungary, Italy, Latvia, Poland, Spain, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedSep 2017
Primary CompletionNov 2020
TodayJul 2026
First PostedSep 15, 2017
Enrollment StartSep 5, 2017
Primary CompletionNov 6, 2020
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 8.8 years ago
Interventions
Netarsudil/Latanoprost 0.02%/0.005%drug
Topical sterile ophthalmic solution
GANFORT®drug
Topical sterile ophthalmic solution